Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy
There is a commercial access agreement for olaparib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback